International experience with tiagabine add-on therapy

Epilepsia
E Ben-Menachem

Abstract

Tiagabine (TGB) hydrochloride is a novel antiepileptic drug (AED) that is a potent and specific inhibitor of gamma-aminobutyric acid (GABA) uptake into glial and neuronal elements. In accordance with medical and regulatory standards, the clinical development program for TGB as an AED has assessed the value of TGB in add-on treatment, focusing mainly on partial seizures, including secondarily generalized seizures. Five add-on, placebo-controlled trials and six noncomparative, open-label, long-term multicenter trials have been or are being conducted in Australia, Europe, and the U.S.A. The results of these trials, involving 2,261 patients, indicate that TGB has efficacy as add-on therapy in patients with epilepsy difficult to control with existing AEDs. Efficacy of TGB is also sustained with long-term treatment. A clear dose-response has been demonstrated, and the minimal effective dose level is 30 mg. TGB is also tolerated, and with long-term therapy no new or more severe types of adverse events develop. These studies have included a wide age range of patients, including adolescents and the elderly.

References

Jun 1, 1983·Epilepsia·P Juul-Jensen, A Foldspang
Apr 1, 1995·Epilepsia·R PacificiC Imperato
Aug 1, 1994·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·B J Wilder
Jan 1, 1994·European Neurology·T Kuntzer

❮ Previous
Next ❯

Citations

Mar 27, 1999·Epilepsy Research·I E LeppikK W Sommerville
Aug 25, 2001·Epilepsia·D M Treiman
Nov 1, 1996·British Journal of Clinical Pharmacology·E Perucca
Mar 24, 1998·Annual Review of Medicine·C W Bazil, T A Pedley
Nov 24, 1998·Journal of Clinical Pharmacology·M S ThomsenT Kruse
Jun 15, 1999·Drug Metabolism and Drug Interactions·A RichensP C Pedersen
Feb 5, 1998·Lancet·J P Leach, M J Brodie
Mar 1, 2000·Drug Metabolism and Drug Interactions·H KastbergK Wesnes
Oct 26, 1999·Epilepsia·S C Schachter
May 13, 1998·Epilepsia·C B DodrillK W Sommerville
Nov 24, 1999·Epilepsia·J M Rho, R Sankar
Jan 1, 1995·Epilepsia·I E Leppik
Jan 7, 2011·Expert Opinion on Pharmacotherapy·Alberto VerrottiFrancesco Chiarelli
Mar 1, 1997·Seminars in Pediatric Neurology·J M Pellock, N Watemberg
May 5, 2001·Expert Opinion on Pharmacotherapy·S C Schachter
Apr 1, 1997·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·E Perucca
Jan 1, 1997·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·C D Ferrie, J H Livingston
Sep 14, 2000·Seizure : the Journal of the British Epilepsy Association·T FakhouryB Abou-Khalil
Jan 31, 2006·Seizure : the Journal of the British Epilepsy Association·Syed Nizamuddin Ahmed, Zaeem A Siddiqi
Aug 25, 2004·Seizure : the Journal of the British Epilepsy Association·Paul McKee
Mar 24, 2016·Journal of Psychopharmacology·James Fm MyersAnne R Lingford-Hughes
Feb 8, 2005·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J Jedrzejczak
Jul 1, 1999·Epilepsia·J A CramerR H Mattson
Jul 17, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jarogniew J LuszczkiStanisław J Czuczwar
Nov 24, 1998·The Annals of Pharmacotherapy·M S Luer, D H Rhoney

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.